These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22005475)

  • 1. Osteonecrosis of the humeral head in a patient with non-small cell lung cancer receiving bevacizumab.
    Koczywas M; Cristea MC
    J Thorac Oncol; 2011 Nov; 6(11):1960-1. PubMed ID: 22005475
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab.
    Katsenos S; Christophylakis C; Psathakis K
    Arch Bronconeumol; 2012 Jun; 48(6):218-9. PubMed ID: 22429334
    [No Abstract]   [Full Text] [Related]  

  • 3. Esophageal fistula after EUS-FNA in a patient treated with bevacizumab for non-small-cell lung cancer.
    Stigt JA; Boomsma MF; de Vos tot Nederveen Cappel WH
    J Thorac Oncol; 2013 Mar; 8(3):e25-6. PubMed ID: 23407564
    [No Abstract]   [Full Text] [Related]  

  • 4. Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer.
    Dowlati A
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S71-5. PubMed ID: 21885002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in lung cancer: lackluster performance and unjustified expense?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Sep; 18(3):381-2. PubMed ID: 22777997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
    Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
    J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and severe acne in a patient treated with bevacizumab.
    Molina-Ruiz AM; Domine M; Requena L
    Int J Dermatol; 2013 Apr; 52(4):486-90. PubMed ID: 23432695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in non-small cell lung cancer: an overview of practice in the era of molecular testing.
    Snee M
    Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):468-72. PubMed ID: 24909702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab.
    D'Antonio C; Viterbo A; Romiti A; Enrici MM; Lauro S; Marchetti P
    J Thorac Oncol; 2012 Feb; 7(2):468-9. PubMed ID: 22252564
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute renal failure in a patient receiving anti-VEGF therapy for advanced non-small cell lung cancer.
    Zhao J; Li H; Wang M
    J Thorac Oncol; 2009 Sep; 4(9):1185-7. PubMed ID: 19704343
    [No Abstract]   [Full Text] [Related]  

  • 11. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
    Gray J; Murren J; Sharma A; Kelley S; Detterbeck F; Bepler G
    J Thorac Oncol; 2007 Jun; 2(6):571-3. PubMed ID: 17545855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.
    Besse B; Le Moulec S; Mazières J; Senellart H; Barlesi F; Chouaid C; Dansin E; Bérard H; Falchero L; Gervais R; Robinet G; Ruppert AM; Schott R; Léna H; Clément-Duchêne C; Quantin X; Souquet PJ; Trédaniel J; Moro-Sibilot D; Pérol M; Madroszyk AC; Soria JC
    Clin Cancer Res; 2015 Apr; 21(8):1896-903. PubMed ID: 25614446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.
    Bettini G; Blandamura S; Saia G; Bedogni A
    BMJ Case Rep; 2012 Oct; 2012():. PubMed ID: 23093510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of bevacizumab in non-small cell lung cancer: an update.
    Lauro S; Onesti CE; Righini R; Marchetti P
    Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases.
    Danciu OC; Rayani S; Michals EA; Villano JL
    Med Oncol; 2012 Dec; 29(4):2619-22. PubMed ID: 22209841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
    Ganapathi AM; Westmoreland T; Tyler D; Mantyh CR
    J Am Coll Surg; 2012 Apr; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
    Hata A; Kaji R; Fujita S; Katakami N
    J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753
    [No Abstract]   [Full Text] [Related]  

  • 18. Osteonecrosis of the jaws and bevacizumab therapy: a case report.
    Brunamonti Binello P; Bandelloni R; Labanca M; Buffoli B; Rezzani R; Rodella LF
    Int J Immunopathol Pharmacol; 2012; 25(3):789-91. PubMed ID: 23058032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.